COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #84
Source   PDF   Share   Tweet
See all 181 studies
Early treatment study
Hong et al., Infect. Chemother., 2020, doi:10.3947/ic.2020.52.e43 (Peer Reviewed)
Early Hydroxych loroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication
HC Q 1-4 days from diagnosis was the only protective factor against prolonged viral shedding found, OR 0.111, p=0.001. 57.1% viral clearance with 1-4 days delay vs. 22.9% for 5+ days delayed treatment. Authors report that early administration of HC Q significantly ameliorates inflammatory cytokine secretion and that COVID-19 patients should be administrated HC Q as soon as possible. 42 patients with HC Q 1-4 days from diagnosis, 48 with HC Q 5+ days from diagnosis.
no virological cure, ↓64.9%, p=0.001, risk of prolonged viral shedding
(odds ratio converted to relative risk)
Source   PDF   Share   Tweet
See all 181 studies
Please send us corrections, updates, or comments.